On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ﾀ150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.

GSK also supported the manufacture of up to 100 million doses of CureVacﾒs first generation COVID-19 vaccine candidate CVnCoV in 2021.